(S)-3-羟基-2-吡咯烷酮 | 34368-52-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (S)-3-羟基-2-吡咯烷酮
• 中文别名: (S)-3-羟基吡咯烷-2-酮
• 英文名称: (S)-3-hydroxypyrrolidin-2-one
• 英文别名: (S)-3-Hydroxy-2-pyrrolidinone；(-)-(S)-3-hydroxy-2-pyrrolidinone；(S)-(-)-3-hydroxypyrrolidin-2-one；(S)-(-)-3-hydroxy-2-pyrrolidone；(3S)-3-hydroxy-2-pyrrolidinone；(3S)-3-hydroxypyrrolidin-2-one
• CAS: 34368-52-0
• 化学式: C₄H₇NO₂
• mdl: MFCD06796625
• 分子量: 101.105
• InChiKey: FRKGSNOMLIYPSH-VKHMYHEASA-N

物化性质

• 熔点：
  100-102 °C(Solv: ethanol (64-17-5); ethyl ether (60-29-7))
• 沸点：
  363.6±35.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少量）、甲醇（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2~8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (S)-3-Hydroxypyrrolidin-2-one
Synonyms: (S)-(-)-3-hydroxy-2-pyrrolidinone

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (S)-3-Hydroxypyrrolidin-2-one
CAS number: 34368-52-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H7NO2
Molecular weight: 101.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-3-羟基-2-吡咯烷酮 在 偶氮二甲酸二异丙酯 、 三苯基膦 、 对硝基苯甲酸 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 8.0h， 以60%的产率得到(R)-3-羟基吡咯烷酮
  参考文献：
  名称：

  CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS

  摘要：

  本文涉及含有咔唑基的酰胺、碳酸酯和脲衍生物，以及其结构式I中的药用可接受盐或水合物，其中变量R1、R2、R3、R4、R5、R6、R7、A、D、E、G、J、L、M、Q、a和b分别描述。还提供了含有式I化合物的药物组合物，用于治疗Cry介导的疾病或紊乱，如糖尿病、与糖尿病相关的并发症、库欣综合征、NASH、NAFLD、哮喘和COPD。

  公开号：

  US20150284362A1
• 作为产物：
  描述：

  (S)-4-amino-2-hydroxybutanoic acid 在 三甲基氯硅烷 、 六甲基二硅氮烷 作用下， 以 邻二甲苯 为溶剂， 生成 (S)-3-羟基-2-吡咯烷酮
  参考文献：
  名称：

  溶剂依赖的非对映异构的Joullié-Ugi三组分反应完全合成Plusbacin A 3及其二脱氧衍生物

  摘要：

  描述了我们对plusbacin A 3（1）的合成研究的全部细节，plusbacin A 3（一种具有抗菌活性的二肽）及其双脱氧衍生物。为了建立有效的1合成路线，使用了溶剂依赖性非对映异构的Joullié-Ugi三组分反应（JU-3CR ），可通过少量步骤构建反式Pro（3-OH）。针对总合成研究了两种策略。在第一个合成策略中，关键步骤是反式JU-3CR和合成最后阶段的大环内酯化。在1,1,1,3,3,3-六氟异丙醇中使用烷基异氰化物的JU-3CR提供了反式产物和片段的偶联以制备大环化前体进行得很顺利。但是，尝试进行大内酯化不能提供所需的产物。然后，研究了在初始阶段包括酯化的第二种策略。使用可转换的异氰酸酯检查了构建反式-Pro（3-OH）的方法，该可转换的异氰酸酯可转换为以下酰胺化所需的羧酸。通过使用羟基-Asp衍生物和相应的醇的分子间偶联来实现酯键的形成，并且酰胺化得到线性的二肽。线性

  DOI：

  10.1021/acs.joc.8b00038

文献信息

• [EN] 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS<br/>[FR] DÉRIVÉS DE 2-OXO-THIAZOLE EN TANT QU'INHIBITEURS DE A2A ET COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE CANCERS
  申请人：ITEOS THERAPEUTICS

  公开号：WO2018178338A1

  公开（公告）日：2018-10-04

  The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to the use of the compounds of Formula (I) for the treatment and/or prevention of cancer. The invention also relates to a process for manufacturing compounds of Formula (I).

  本发明涉及式（I）的化合物或其药用可接受的盐或溶剂化合物。该发明进一步涉及将式（I）的化合物用作A2A抑制剂。该发明还涉及将式（I）的化合物用于治疗和/或预防癌症。该发明还涉及一种制造式（I）化合物的方法。
• Selective NR2B Antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US20150191452A1

  公开（公告）日：2015-07-09

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及到I式化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是NR2B受体的配体，可能对治疗中枢神经系统的各种疾病有用。
• [EN] 4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS<br/>[FR] INHIBITEURS DE DGAT1 À BASE DE 4-AMINO-7,8-DIHYDROPYRIMIDO[5,4,F][1,4]OXAZÉPIN-5(6H)-ONE
  申请人：ASTRAZENECA AB

  公开号：WO2011121350A1

  公开（公告）日：2011-10-06

  DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, diabetes and obesity wherein, R1, R2, R3, R4, X2, q, Y1, Y2, n, Q and Z are as defined in the description.

  DGAT-1抑制剂化合物公式(I)，药用可接受的盐和前药，以及药物组合物、制造它们的方法以及它们在治疗例如糖尿病和肥胖症中的用途，其中，R1、R2、R3、R4、X2、q、Y1、Y2、n、Q和Z在描述中定义。
• Synthesis and Structure-activity Relationships of a Novel Oral Carbapenem, CS-834.
  作者：MASAO MIYAUCHI、ROKURO ENDO、MASAFUMI HISAOKA、HIROSHI YASUDA、ISAO KAWAMOTO

  DOI：10.7164/antibiotics.50.429

  日期：——

  We have studied an ester prodrug of a carbapenem to develop a potent orally active β-lactam antibiotic. A variety of 1β-methylcarbapenem derivatives have been synthesized. We have found that some derivatives having an amide group in the C-2 side chain show potent and well balanced antibacterial activities as well as high stability against dehydropeptidase-I. Oral absorption of derivatives has been optimized by modifying the C-3 ester promoiety. Pivaloyloxymethyl (1R, 5S, 6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-[(R)-5-oxopyrrolidin-3-ylthio]-1-carbapen-2-em-3-carboxylate, CS-834, has been selected as the most promising compound for further evaluation.

  我们研究了一种碳青霉烯酯类前药，旨在开发一种强效的口服活性β-内酰胺抗生素。合成了一系列1β-甲基碳青霉烯衍生物。我们发现，一些在C-2侧链中含有酰胺基团的衍生物显示出强大的且平衡的抗菌活性，并且对脱氨�酶-I具有高稳定性。通过修饰C-3酯的前体部分，优化了衍生物的口服吸收。Pivaloyloxymethyl (1R, 5S, 6S)-6-[(R)-1-羟基乙基]-1-甲基-2-[(R)-5-氧代吡咯烷-3-基硫]-1-碳青霉烯-2-em-3-羧酸酯，CS-834，已被选为最具前景的化合物进行进一步评估。
• TNF -Alpha Modulating Benzimidazoles
  申请人：UCB Biopharma SPRL

  公开号：US20150152065A1

  公开（公告）日：2015-06-04

  A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列苯并咪唑衍生物，作为人类肿瘤坏死因子α活性的强效调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经和神经退行性疾病；疼痛和痛觉障碍；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。